InflaRx (IFRX) Cash from Discontinued Operations (2017)

InflaRx (IFRX) posted Cash from Discontinued Operations of 3754327.12 for Q3 2017.

InflaRx (IFRX) Cash from Discontinued Operations (2017) Analysis & Trends

InflaRx has reported Cash from Discontinued Operations for 1 years, with the latest figure at 3754327.12 in Q3 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Discontinued Operations (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	InflaRx	140.30 Mn	-43.96 Mn	2.74 Bn	-

Download Data

Date	Value
Sep 30, 2017	-3.75 Mn
Sep 30, 2017	-3.75 Mn